Research
Energy balance
Oral semaglutide at a dose of 25 mg once daily resulted in a mean reduction in body weight of -13.6% from baseline to week 64.
Oral semaglutide may be an effective treatment option for weight loss in adults with obesity.
StrongSupportsmedium confidence
The estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group.
Why this rating
Based on a large randomized controlled trial design.
Source
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Sean Wharton et al. · New England Journal of Medicine · 2025
DOI 10.1056/nejmoa2500969
rct · n=307Cited 52×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Participants in the oral semaglutide group were significantly more likely to achieve body-weight reductions of 5% or more, 10% or more, 15% or more, and 20% or more compared to the placebo group.Strong
- Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% vs. 42.2%).Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →